Who
John Markels
Director
Company insider
Files Form 4 as: Director, Vaxcyte; Director, Arcturus Therapeutics Holdings; Director, Sangamo Therapeutics.
In numbers
- Trades disclosed
- 25
- Buys
- 1
- Sells
- 0
- Bought
- $25K
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 11 Feb 2020
- Last trade
- 16 Jul 2026
- Last filed
- 16 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jul 2026filed 16 Jul 2026 | PCVX Vaxcyteoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,029 at $0.00 | filing |
| 16 Jul 2026filed 16 Jul 2026 | PCVX Vaxcyteoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,029 at $0.00 | filing |
| 5 Jun 2026filed 15 Jun 2026 | ARCT Arcturus Therapeutics Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 5 Jun 2026filed 15 Jun 2026 | ARCT Arcturus Therapeutics Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 12 Jun 2025filed 16 Jun 2025 | Sangamo Therapeuticsoption or derivative | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 12 Jun 2025filed 16 Jun 2025 | Sangamo Therapeutics | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 9 Jun 2025filed 11 Jun 2025 | ARCT Arcturus Therapeutics Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 14 Jun 2024filed 18 Jun 2024 | ARCT Arcturus Therapeutics Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,131 at $0.00 | filing |
| 14 Jun 2024filed 18 Jun 2024 | ARCT Arcturus Therapeutics Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 14 Jun 2024filed 18 Jun 2024 | ARCT Arcturus Therapeutics HoldingsBiotechnology | SEC FORM 4 Code M | —3,131 at $0.00 | filing |
| 4 Jun 2024filed 6 Jun 2024 | Sangamo Therapeuticsoption or derivative | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 4 Jun 2024filed 6 Jun 2024 | Sangamo Therapeutics | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 1 Aug 2023filed 3 Aug 2023 | ARCT Arcturus Therapeutics Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,869 at $0.00 | filing |
| 1 Aug 2023filed 3 Aug 2023 | ARCT Arcturus Therapeutics Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,131 at $0.00 | filing |
| 1 Jun 2023filed 5 Jun 2023 | Sangamo Therapeuticsoption or derivative | SEC FORM 4 Code A | —27,750 at $0.00 | filing |
| 1 Jun 2023filed 5 Jun 2023 | Sangamo Therapeutics | SEC FORM 4 Code A | —13,900 at $0.00 | filing |
| 8 Dec 2022filed 13 Dec 2022 | ARCT Arcturus Therapeutics Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 8 Dec 2022filed 13 Dec 2022 | ARCT Arcturus Therapeutics Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,986 at $0.00 | filing |
| 3 Jun 2022filed 6 Jun 2022 | Sangamo Therapeutics | SEC FORM 4 Bought | $25K6,784 at $3.69 | filing |
| 25 Feb 2022filed 1 Mar 2022 | Sangamo Therapeuticsoption or derivative | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.